terlipressin

SUSPENDED · PHASE4 · Cirrhosis, Hepatorenal Syndrome

because in a preliminary analysis we would need 1000 patients per group to achieve significative differences in the main end point.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.